Agilent Technologies last week said it plans to launch later this month its SureSelect Target Enrichment System, which is designed to enable scientists to sequence genomic areas of interest with second-generation sequencing instruments.

According to Agilent, researchers can use the platform to capture a subset of exons or other genome targets and wash away the rest of the genome prior to sequencing. The company views the product as a replacement for what it calls “labor-intensive” methods for targeted re-sequencing, such as PCR.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.